Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy

Table 3

Treatment-related adverse events in the study population.

Variables	Olanzapine 5 mg			Olanzapine 10 mg
	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
Somnolence	26 (34.7%)	5 (6.7%)	0	34 (45.3%)	9 (12%)	1 (1.3%)	0.034
Constipation	13 (17.3%)	2 (2.7%)	0	14 (18.7%)	4 (5.3%)	0	0.554
Hiccups	6 (8%)	1 (1.3%)	0	7 (9.3%)	1 (1.3%)	0	0.785